Unlearn leverages generative AI to create digital patient twins, transforming the clinical trials landscape by enabling more efficient and reliable drug development. Through reducing the size of control groups, Unlearn is pioneering a new era of ethical drug development that allows more trial patients to get access to novel therapeutics and allows drugs to get to market faster. Unlearn is at the forefront of clinical trial innovation and counts many of the top pharmaceutical companies as customers.

Our other investment companies